Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 29, 2026, 7:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–18 of 18 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Lotion vehicle/placebo Clear all
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 for the Treatment of Acne Vulgaris

NCT03290027
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03, Placebo Comparator
Drug · Other
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Plano, Texas
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Clinical Endpoint Study of Ivermectin 0.5% Lotion

NCT03301649
View directory record Official record
Conditions
Head Lice
Interventions
Generic Ivermectin Lotion 0.5%, Sklice® (Ivermectin) Lotion 0.5%, Vehicle Lotion
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
6 Months and older
Enrollment
905 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 19, 2019 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea

NCT03287791
View directory record Official record
Conditions
Rosacea
Interventions
Generic Azelaic Acid Foam, Finacea® (Azelaic Acid) Foam, Vehicle Foam, Cleanser, Sunscreen, Towel, Moisturizing Lotion
Drug · Other
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
924 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
26
States / cities
Encino, California • La Mesa, California • Brandon, Florida + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

A Clinical Study to Evaluate the Long-Term Efficacy and Tolerability of a Daily Anti-Aging Daily Serum

NCT05514782
View directory record Official record
Conditions
Photoaging, Wrinkle
Interventions
Cleansing Lotion, Facial Moisturizer, Sunscreen SPF 40+
Other
Lead sponsor
Revision Skincare
Industry
Eligibility
30 Years to 60 Years · Female only
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Chester, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 26, 2022 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Bioequivalence Study for Benzyl Alcohol Lotion 5%.

NCT02624843
View directory record Official record
Conditions
Head Lice
Interventions
Benzyl Alcohol Lotion 5%, Ulesfia (benzyl alcohol lotion) 5%, Placebo
Drug
Lead sponsor
Akorn, Inc.
Industry
Eligibility
6 Months to 60 Years
Enrollment
239 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
4
States / cities
Los Angeles, California • Miami, Florida • Plantation, Florida
Source: ClinicalTrials.gov public record
Updated Jan 26, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Topical Acetyl Hexapeptide-8 and the Cosmetic Appearance of Oily Skin

NCT02597777
View directory record Official record
Conditions
Oily Skin
Interventions
Acetyl Hexapeptide-8, Placebo vehicle
Other
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

A Study Comparing Halobetasol Propionate and Tazarotene Topical Lotion 0.01%/0.045% to Duobrii® Lotion (Halobetasol Propionate and Tazarotene Lotion), 0.01%/0.045% (Reference Listed Drug) in the Treatment of Moderate to Severe Plaque Psoriasis.

NCT05282771
View directory record Official record
Conditions
Plaque Psoriasis
Interventions
Halobetasol Propionate and Tazarotene Lotion 0.01%/0.045%, Duobrii® Lotion (Halobetasol propionate and tazarotene lotion), 0.01%/0.045%, Placebo
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 15, 2022 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

Bioequivalence Study of Clindamycin Phosphate Topical Lotion, 1% in Subjects With Acne Vulgaris

NCT03717506
View directory record Official record
Conditions
Acne Vulgaris
Interventions
GDC 268 Lotion, Clindamycin Phosphate Lotion 1%, GDC Vehicle Lotion
Drug
Lead sponsor
Balmoral Medical company
Industry
Eligibility
12 Years to 40 Years
Enrollment
1,236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
34
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Fountain Valley, California + 31 more
Source: ClinicalTrials.gov public record
Updated May 3, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Bioequivalence Study, Comparing Two Formulations of Ivermectin Lotion, 0.5%

NCT03257943
View directory record Official record
Conditions
Lice; Head Lice
Interventions
Ivermectin Lotion, 0.5%, SKLICE (ivermectin) Lotion, 0.5%, Vehicle of the Test product
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
18 Years and older
Enrollment
413 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
1
States / cities
Hawthorne, New York
Source: ClinicalTrials.gov public record
Updated May 17, 2018 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 2 Interventional Results available

A Study to Determine the Efficacy and Safety of Halobetasol Propionate Lotion 0.05% in Subjects With Plaque Psoriasis

NCT01610596
View directory record Official record
Conditions
Psoriasis, Plaque Psoriasis
Interventions
Halobetasol Propionate Lotion 0.05%, Placebo
Drug
Lead sponsor
Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
3
States / cities
San Diego, California • Fridley, Minnesota • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 12, 2016 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

5% Sodium L-Ascorbyl-2-Phosphate Lotion for the Treatment of Acne Vulgaris

NCT00714454
View directory record Official record
Conditions
Acne Vulgaris
Interventions
APS Topical Lotion, Placebo
Other
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 39 Years
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Miami Beach, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2008 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study to Evaluate the Effect of Ha44 Gel on the Electrocardiogram in Healthy Volunteers

NCT01518699
View directory record Official record
Conditions
Pediculosis
Interventions
Ha44, Ha44 Placebo, Moxifloxacin Placebo, Moxifloxacin
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years to 50 Years
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 8, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Randomized, Double-Blind Evaluation of Maple Leaf Extract (Maplifa) for Photoaging

NCT04586816
View directory record Official record
Conditions
Photoaging, Hyperpigmentation, Rhytides
Interventions
1% red maple leaf extract in cream base, 5% red maple leaf extract, vehicle
Combination Product
Lead sponsor
Integrative Skin Science and Research
Industry
Eligibility
30 Years to 70 Years · Female only
Enrollment
19 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Oct 13, 2020 · Synced Sep 29, 2026, 7:18 AM EDT
Terminated Phase 3 Interventional

Naloxone Hydrochloride Study for Relief of Pruritus in Patients With MF or SS Forms of CTCL

NCT02811783
View directory record Official record
Conditions
Mycosis Fungoides, Lymphoma, T-Cell, Cutaneous, Sézary Syndrome
Interventions
Naloxone Hydrochloride Lotion, 0.5%, Placebo Lotion
Drug
Lead sponsor
Elorac, Inc.
Industry
Eligibility
21 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
Little Rock, Arkansas • Duarte, California • Palo Alto, California + 11 more
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Safety and Efficacy of DFD-03 Lotion in the Treatment of Acne Vulgaris for 12 Weeks

NCT03292640
View directory record Official record
Conditions
Acne Vulgaris
Interventions
DFD-03 (0.1% tazarotene) Lotion, DFD-03 (0% tazarotene) Lotion (Placebo)
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
9 Years and older
Enrollment
547 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Fremont, California
Source: ClinicalTrials.gov public record
Updated Feb 28, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 1 Interventional

Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris

NCT04321070
View directory record Official record
Conditions
Acne Vulgaris
Interventions
Clindamycin Phosphate, Clindamycin Phosphate RLD, Placebos
Drug
Lead sponsor
Sun Pharmaceutical Industries, Inc.
Industry
Eligibility
12 Years to 40 Years
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Charlotte, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 9, 2025 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Dermal Safety Study to Evaluate Potential Irritation of Abametapir Lotion

NCT02061813
View directory record Official record
Conditions
Head Lice
Interventions
Abametapir Lotion 0.74% w/w, Sodium Lauryl Sulfate, Saline 0.9%, Placebo
Drug
Lead sponsor
Dr. Reddy's Laboratories Limited
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Paramus, New Jersey
Source: ClinicalTrials.gov public record
Updated Jul 25, 2021 · Synced Sep 29, 2026, 7:18 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RTA 408 Lotion in Healthy Volunteers

NCT02029716
View directory record Official record
Conditions
Healthy
Interventions
RTA 408 Lotion 0.5%, 1%, 3%, Lotion vehicle/placebo
Drug
Lead sponsor
Biogen
Industry
Eligibility
18 Years to 65 Years
Enrollment
109 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 27, 2025 · Synced Sep 29, 2026, 7:18 AM EDT